Mutation status of refractory to imatinib patients with chronic myeloid leukemia
Mutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and secondary imatinib resistance was analyzed. BCR-ABL mutations identified by direct DNA sequencing. BCR-ABL kinase domain mutations were detected in 30.5 % (11 of 36) of those patients. Most of identified...
Main Authors: | E. G. Ovsyannikova, K. D. Kaplanov, T. Yu. Klitochenko, A. V. Misyurin, I. L. Davydkin, L. V. Zaklyakova, E. A. Popov, B. N. Levitan |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-07-01
|
Series: | Onkogematologiâ |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/72 |
Similar Items
-
Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01) -
Imatinib en leucemia mieloide crónica Imatinib in chronic myeloid leukemia
by: Valia Pavón Morán, et al.
Published: (2005-12-01) -
Complete molecular response induced by nilotinib in a patient previously treated with imatinib, nilotinib and dasatinib
by: Giuseppe Pietrantuono
Published: (2015-10-01) -
Mutations Associated with Imatinib Mesylate Resistance - Review
by: Linev Alexandar J., et al.
Published: (2018-12-01) -
Nilotinib efficacy in a patient resistant to imatinib
by: Luigia Luciano
Published: (2015-10-01)